PolyPid Ltd. (PYPD) Stock Score, Valuation & Financial Research

PolyPid Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PYPD

PolyPid Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 4.83. These figures are a research snapshot, not a buy or sell recommendation.

What PolyPid Ltd. does

PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

PolyPid is a late-stage biopharmaceutical company that develops proprietary, locally administered, controlled, prolonged-release therapeutics. The company utilizes its PLEX (Polymer-Lipid Encapsulation matriX) technology to pair with Active Pharmaceutical Ingredients, aiming to generate revenue through the future commercialization of its product candidates, such as D-PLEX100, once regulatory approvals are obtained.

Products and services

  • The company's primary product candidate is D-PLEX100, a locally administered, prolonged-release antibiotic designed for the prevention of surgical site infections. The company also maintains an innovative pipeline targeting oncology, obesity, and diabetes.

Brands and product families

  • D-PLEX100 — Lead product candidate for the prevention of abdominal colorectal surgical site infections. Source

Customer types

Hospitals and surgical centers.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Azurity Pharmaceuticals — A commercial collaboration and license agreement for the development and commercialization of certain product candidates. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — Companies developing alternative surgical site infection prevention therapies or other local drug delivery systems. Source

Business strengths to evaluate

  • Proprietary PLEX technology platform Source

Business risks and research considerations

  • Dependence on clinical trial success and regulatory approval Source
  • History of operating losses and need for additional capital Source

Sources: Company research source · Azurity Pharmaceuticals

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PYPD financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.83
Market capitalization:
98.11M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -31.5M
Free cash flow:
USD 0.00
Cash:
USD 6.56M
Total debt:
USD 1.57M
EPS:
USD -1.48

What stands out

  • Free cash flow is USD 0.00, zero for the stored period.
  • The balance sheet shows USD 6.56M of cash versus USD 1.57M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 4.99M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PYPD

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Why is PYPD's stored free cash flow zero, and do the filing and calculation confirm that value?
  • How is PYPD likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PYPD to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PYPD's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PYPD

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.